What do patients need to know about apotex's ruxolitinib inactive ingredients?
Ruxolitinib is a medication used to treat myelofibrosis, a type of bone marrow disorder. Apotex produces a generic version of ruxolitinib [1]. According to the medication's label, some of the inactive ingredients in Apotex's ruxolitinib include lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and silicon dioxide [2].
What are the risks associated with these inactive ingredients?
While the inactive ingredients are generally considered safe, there may be potential risks for patients with certain allergies or sensitivities. For example, lactose is a common allergen and may cause issues for patients with lactose intolerance. Additionally, some patients may be sensitive to the other inactive ingredients listed, such as microcrystalline cellulose or magnesium stearate.
Can patients take apotex's ruxolitinib if they have specific allergies?
If patients have a history of allergies to lactose or other inactive ingredients, they should consult their doctor before taking apotex's ruxolitinib. The doctor can help determine whether the potential benefits of the medication outweigh the risks associated with the inactive ingredients.
What are some alternative medications for patients with concerns?
For patients who are concerned about the inactive ingredients in apotex's ruxolitinib, their doctor may consider alternative medications for treating myelofibrosis. These may include other JAK inhibitors, such as tofacitinib or baricitinib, which have different inactive ingredients.
When does the patent for ruxolitinib expire, and what may happen to competition?
The patent for ruxolitinib, held by Incyte Corporation, is set to expire in 2027 [3]. At that time, more generic versions of the medication may become available, potentially providing increased competition and driving costs down. However, this may also impact the availability of the medication and pricing.
Sources:
[1] DrugPatentWatch.com (2023). Ruxolitinib (Generic). Retrieved June 14, 2023, from https://www.drugpatentwatch.com/drugs/ruxolitinib
[2] Apotex (2023). Ruxolitinib Tablets. Retrieved June 14, 2023, from https://cdn.apotex.ca/hcp/Ruxolitinib-Tabs.pdf
[3] DrugPatentWatch.com (2023). Ruxolitinib (Jakafi) Patent Expiration. Retrieved June 14, 2023, from https://www.drugpatentwatch.com/patent/jakafi-ruxolitinib/